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AbstrACt
Introduction Improved medicines’ management could 
lead to real and sustainable improvements to the care 
of older adults. The overuse of mental health medicines 
has featured in many reports, and insufficient patient 
monitoring has been identified as an important cause of 
medicine-related harms. Nurse-led monitoring using the 
structured adverse drug reaction (ADRe) profile identifies 
and addresses the adverse effects of mental health 
medicines. Our study investigates clinical impact and what 
is needed to sustain utilisation in routine practice in care 
homes.
Methods and analysis This process evaluation will use 
interviews and observations with the participants of all 
five homes involved in earlier research, and five newly 
recruited homes caring for people prescribed mental 
health medicines. The ADRe profile is implemented by 
nurses, within existing resources, to check for signs 
and symptoms of ADRs, initiate amelioration and 
share findings with pharmacists and prescribers for 
medication review. Outcome measures are the numbers 
and nature of problems addressed and understanding 
of changes needed to optimise clinical gain and sustain 
implementation. Data will be collected by 30 observations 
and 30 semistructured interviews. Clinical gains will be 
described and narrated. Interview analysis will be based 
on the constant comparative method.
Ethics and dissemination Ethical approval was 
conferred by the National Health Service Wales Research 
Ethics Committee. If the ADRe profile can be sustained in 
routine practice, it has potential to (1) improve the lives 
of patients, for example, by reducing pain and sedation, 
and (2) assist in early identification of problems caused by 
ADRs. Therefore, in addition to peer-reviewed publications 
and conferences, we shall communicate our findings 
to healthcare professionals, policy-makers and sector 
regulators.
trial registration number NCT03110471.
bACkground
The success of the WHO Third Global Patient 
Safety Challenge on Medication Safety will 
depend on effective strategies to address 
concerns that ‘medicines sometimes cause 
serious harm if taken incorrectly, monitored 
insufficiently or as the result of errors, acci-
dents or communication problems’.1 Meeting 
the challenge of insufficient monitoring will 
demand innovation and change to current 
practice. Most adverse drug reactions (ADRs) 
or side effects (glossary, online supplemen-
tary file 1) are due to poor monitoring, not 
poor prescribing.2–6 
strengths and limitations of this study
 ► This intervention is the first simple, low-risk, low-
cost, multidisciplinary strategy to check patients 
comprehensively for potential adverse effects of 
their medicines and ameliorate any harms identified.
 ► For the last decade, some 5%–8% of UK unplanned 
hospital admissions have been caused by adverse 
drug reactions (ADRs), most of which were prevent-
able. Our intervention has potential to address this 
situation, but sustainability needs to be tested.
 ► The intervention was effective in a pragmatic ran-
domised controlled trial, but a qualitative explora-
tion of how it embeds into routine care is needed 
to highlight (1) how clinical gains are achieved 
and (2) the barriers to and facilitators of sustained 
implementation.
 ► We are working with volunteer care homes in South 
West Wales, and the transferability of findings will 
depend on readers’ interpretations of their practical 
adequacy and professionals’ assessment of the im-
portance of using ADRe.
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Preventable ADRs have proven an intractable problem 
over the last decade, causing 5%–8% of unplanned UK 
hospital admissions,7 8 costing the National Health Service 
(NHS) £1bn–2.5bn each year.9 The problem is at least 
as extensive in developing countries, at ~10% of admis-
sions.10 Most adverse drug events (ADEs) (glossary, online 
supplementary file 1), ADRs (glossary, online supplemen-
tary file 1) and medicines’ mismanagement (including 
errors by patients and professionals) are preventable,8 11 
but there are no comprehensive systematic approaches to 
the problem.
Some 50% of residents in UK care homes (glossary, 
online supplementary file 1) are prescribed mental health 
medicines,12 doses in care homes13 and primary care14 are 
often excessive, 4.8%–37% of older people with cognitive 
impairment have ADRs15 and the proportion of care home 
residents exposed to inappropriate medications (any) 
ranges from 34% (definition from the Swedish National 
Board of Health and Welfare)16 to >50% (definitions 
based on instruments selected by each study author).17 
ADRs to mental health medicines can be life-threat-
ening (eg, cardiac arrhythmias, cardiac hypofunction) 
or debilitating (eg, drug-induced Parkinsonism, ataxia, 
postural hypotension) or subtle and mistaken for signs of 
ageing or underlying pathology. They can be overlooked, 
leading to behaviour problems, xerostomia, constipation, 
poor food and/or fluid intake, tremor, restlessness, seda-
tion, pain, double incontinence or other problems, all 
causing potential loss of comfort and dignity.18 19 Eigh-
teen per cent of 13 699 UK primary care incident reports 
and 24% of 996 deaths or serious harms recorded from 
2005 to 2013 were attributed to prescription medicines 
(any), mainly avoidable ADRs, largely due to inadequate 
monitoring, communication or decision-making.20 We 
suggest that this care gap can be closed by formalised 
structured medicines’ monitoring.19 21–24
A consensus is emerging around overprescribing in care 
homes,13 14 16 25 26 and this work is now a priority for Welsh 
government. However, there is less agreement regarding 
the changes needed in routine care,1 27–29 and reviewers 
indicate that evidence supporting single-profession 
interventions is equivocal.11 29–34 The UK Department of 
Health’s National Dementia Strategy, launched 2009,13 and 
Medicines and Healthcare products Regulatory Agency 
recommendations35 have not reduced antipsychotic 
prescribing,36 whereas the ADRe Profile succeeded in a 
randomised controlled trial (RCT).19 ADRe, formerly the 
West Wales ADR Profile, is available, with further informa-
tion, on our website (http://www. swansea. ac. uk/ adre/). 
It has potential to reduce costs,19 while addressing 
concerns over care quality,25 27 28 37 medicines’ overuse,14 
and the responsibility of those administering medicines 
to report patients’ changes to prescribers, despite time 
constraints limiting face-to-face multidisciplinary team 
meetings.38
The Food and Drug Administration warning on antipsy-
chotic prescribing was followed by a shift towards increased 
use of benzodiazepines,39 and there is no evidence of 
benefit from long-term antidepressants in older adults40; 
therefore, to ensure a comprehensive approach, ADRe 
includes all current mental health medicines. When used 
by nurses, both registered nurses and nursing assistants, 
ADRe has improved quality of care by addressing phys-
ical health issues for all patients monitored and identi-
fying and addressing serious adverse events in ~10% of 
patients. Examples of previously unsuspected problems 
that we identified and addressed include: cardiac arrhyth-
mias and severe hypertension,21 drug-induced Parkin-
sonism,23 respiratory tract infections,41 pain and nausea,19 
chest pain and valproate-induced pancreatitis.24 No 
harms have been reported from use of ADRe. We now 
aim to explore what is needed to optimise clinical gains 
and sustain implementation of ADRe in routine practice 
(figure 1).
study dEsIgn And MEthods
This evaluation will integrate data from observations and 
interviews to explore clinical gains and any challenges in 
delivering the intervention, differences between inten-
tions and delivery, the best way to embed medicines’ 
monitoring into practice and relationships between 
ADRe, clinical contexts and processes and outcomes of 
care.42 43
sEttIng
We are working with 10 care homes in Abertawe Bro 
Morgannwg University Health Board (ABMUHB) whose 
management teams have volunteered to participate. This 
includes all five care homes involved in a previous study, 
who are best placed to report on sustainability,19 and five 
new care homes. ABMUHB is in a region of South West 
Wales that receives EU convergence funding because GDP 
is below 75% of the community mean.44 It serves a popu-
lation of 525 000 (33 000 aged 75–84 years and 13 000 
over 85 years).45 Care homes are governed by legislation46 
and regularly inspected to ensure they meet prespecified 
standards.47 Regularity of contact between care homes 
and pharmacists, consultants and general practitioners 
(GPs) varies across South West Wales.
PArtICIPAnts
Inclusion criteria for care homes are: providing residen-
tial or nursing care or both to >4 service users meeting 
the inclusion criteria (vi) and willing to use ADRe in 
routine practice. We excluded three homes participating 
in a previous feasibility study, as they are affiliated to a 
home that is already participating, which would have 
introduced ties into the data,23 and homes with <5 resi-
dents meeting the inclusion criteria or unwilling or 
unable to volunteer to undertake nurse-led medicines’ 
monitoring.
The target population for mental health medi-
cines’ monitoring is people receiving at least one of: 
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antipsychotics, antiepileptics/mood stabilisers, antide-
pressants, anxiolytics or hypnotics (benzodiazepines 
or Z drugs). Eligibility for ADRe is based on medicines 
prescribed, and, previously,19 23 we found it impractical to 
search service users’ records to determine diagnostic cate-
gories or indications for prescribing. Therefore, we are 
using medication administration record (MAR) charts to 
identify potential participants taking at least one of the 
mental health medicines being monitored. (In the UK, 
these do not record indications for prescriptions.) Three 
residents per care home are being observed during one 
completion of ADRe. Inclusion criteria are: resident at 
the home and expected to continue for 1 year; currently 
taking any of the medicines listed above; willing and able 
to give informed, signed consent themselves or where 
capacity is lacking, having a consultee (see Consent, 
below) willing to give advice. We exclude those not 
well enough to participate, as screened by their nurses, 
aged <18 years or receiving active palliative care.
Stakeholder interviews are being conducted with the 
study’s care home leads (nurses, nurse managers, matrons 
or managers), residents, service users or their families, 
prescribers, pharmacists and key stakeholders, including 
strategic leads, and the care home inspectorate.48
recruitment
All 45 eligible care homes in ABMUHB were contacted 
by email, and at events disseminating previous research 
findings,19 to seek five volunteers for this new study. 
Where a home expressed interest, the manager was sent 
detailed information. The first to respond positively 
were recruited, visited and trained in using ADRe until 
the target number was reached. Managers are asked to 
identify volunteer project leads and embed ADRe into 
routine practice before observation is arranged. Service 
users to be observed are recruited by their nurses, based 
on inclusion criteria; this involves using their professional 
judgement. Professionals and service users for interview 
are nurses and, where possible, residents or service users 
from the 10 care homes and stakeholders identified by 
snowball sampling. Respondents receive information 
sheets and are followed up a week later to arrange inter-
view locations, dates and times of mutual convenience 
(figure 2).
sample size
There are no fixed rules for sample size in qualitative 
research.49 50 The study addresses focused questions in a 
field where we have past experience.21 51 52 We anticipate 
that 20–30 interviews and 20–30 observations will permit 
sufficiently powerful analyses53: 30 transcripts will allow 
for 4–5 themes (see Analysis) at 50% prevalence with 
10 instances with 90% power.54 We anticipate that these 
numbers will achieve data saturation (in the sense of no 
new information being forthcoming and no new themes 
or categories being generated), assuming that common 
themes are mentioned by the diverse stakeholders; 
we hold open the possibility of additional interviews if 
important issues remain unclear.
Patient and public involvement
Our intervention and research design developed as 
we incorporated service users’ suggestions as the work 
evolved. Service users were actively involved in the 
design and redesign of the ADRe profiles by cognitively 
testing and reshaping the questions and scrutinising 
drafts,19 23 41 55 56 together with clinicians22 and stake-
holders (patient representatives, care home staff, social 
workers) in interviews and focus groups.21 41 48 Service 
users contributed to the development of this study and 
Figure 1 The medication chain.
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will be invited to our dissemination event. Updates and 
research papers will be sent to participating care homes 
for dissemination to participating residents and their 
visitors.
Intervention
Structured, standardised patient questioning improves 
ADR reporting.57 ADRe asks nurses to systematically check 
patients for the manifestation of itemised adverse side 
effects (glossary, online supplementary file 1) or unde-
sirable effects of their mental health medicines, as listed 
in the British National Formulary (BNF) and manufac-
turers’ Summaries of Product Characteristics (SmPCs), 
and seminal texts documenting known ADRs.58 59 We 
are developing a formalised approach to monitoring all 
patients prescribed mental health medicines, regardless of 
diagnostic categories. The ADRe profile for mental health 
medicines was introduced to address nurses’ and patients’ 
concerns that patients’ ADRs were neither recognised nor 
communicated to prescribers. It evolved from a teaching 
innovation55 through before and after,22 24 inter-rater reli-
ability56 and feasibility studies23 and an RCT19 to a clini-
cally effective, evidence-based intervention.22–24 52 56 ADRe 
opens dialogue with patients and provides the informa-
tion needed to answer key questions:
 ► Are there previously unrecognised or unmonitored 
problems, such as postural hypotension, irregular 
Figure 2 Participant flow diagram. ABMUHB, Abertawe Bro Morgannwg University Health Board.  on
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heart rate, posture/movement disorders, pain or 
nausea that might be better managed?
 ► Should care plans be modified to address these 
problems?
 ► Would any of these problems be alleviated if medica-
tion doses, formulations or administration times were 
changed?
 ► Are any prescribed medicines likely causing more 
problems than they are alleviating?
ADRe offers a strategy to prevent ADRs becoming serious 
and improve care quality by: (1) regular systematic checks 
and documentation of problems, however subtle, listed as 
‘side’ or ‘undesirable’ effects in formularies and SmPCs; 
(2) transfer of information to prescribers25 27 28 37 38; 
(3) integration with NHS, for example, contacts with 
prescribers (GPs and specialists), dentists and opti-
cians60 and (4) synergy with pharmacist reviews to opti-
mise therapeutic regimens.
During routine care, nurses work through the list with 
patients, address some problems themselves and feedback 
to pharmacists or prescribers (see figure 1). Some ADRe 
items identify where additional nursing care is needed to 
mitigate the adverse effects of medicines, for example, 
drug-induced xerostomia may be limiting eating and 
warrant additional oral care and dental examinations, 
or recording tremor or ataxia may trigger reassessment 
of risks of falls. Other problems require discussion 
with prescribers or referral to specialists and help from 
multidisciplinary teams (for example, pain, nausea, rest-
lessness, behaviour problems)19 22 52 (figure 3, online 
supplementary file 2). Therefore, we adapted ADRe to 
enhance team working with pharmacists.1 25 26 Pharma-
cists and prescribers do not always have time to engage 
fully with patients to obtain their perspectives61 or obtain 
details of signs and symptoms such as continence or 
bowel movements, particularly where patients are unable 
to verbalise: ADRe fills this communication gap.
Targeted questions identify ‘side’ or ‘undesirable 
effects’, as these signs and symptoms may indicate 
ADRs,58 59 62 and merit attention regardless of aetiology. 
For example, tremor may indicate drug-induced Parkin-
sonism caused by antipsychotics or antiepileptics, but, 
as suggested in supporting information, alternative aeti-
ologies warrant consideration: beta2 agonists or other 
stimulants, tramadol, fentanyl, hyperthyroidism, hypogly-
caemia, anticholinesterases, alcohol misuse or dementia. 
Only careful review of medication records and patient 
history, usually in collaboration with pharmacist or 
prescriber, will identify likely causes and any candidate 
medicines for dechallenge. Rechallenge is not a normal 
practice in the UK, and specific laboratory tests are 
rarely available.63 ADRe also includes health promotion/
prevention advice that is particularly pertinent to users 
of mental health medicines. For example, xerostomia 
caused by antipsychotic and other antimuscarinic medi-
cines promotes dental caries,64 and ADRe asks nurses 
to check that service users have visited their dentists in 
the last year. Assessment of possible or likely aetiology 
rests with clinicians delivering care, as does the decision 
regarding the advisability of any dechallenge or depre-
scribing. Formal assessments of ADR causality65 cannot 
confer certainty or prove a connection or quantify a 
contribution63 and rarely achieve consensus.65 However, 
prescribers and care staff need to make practical assess-
ments as to amelioration of problems. Therefore, we are 
sometimes less equivocal regarding health promotion 
measures and the advisability of investigating the full 
range of possible causes of problems. For example, where 
a tremor is detected, it is often worthwhile to review use 
of alcohol and stimulants, such as cold cures or caffeine, 
and consider the possibility of hypoglycaemia if antidia-
betic agents are administered.
‘Unique selling points’ and distinguishing features of ADRe
Searches56 66–68 and reviews69 70 have not identified other 
comprehensive nurse-led instruments for checking 
patients’ reactions to mental health medicines.2 56 66 71 
Searching English language work for ‘adverse drug reac-
tions’ (as a MeSH entry term), nursing (as nurs*) and 
‘monitoring’ in PubMed and the Cochrane library iden-
tified only two groups with empirical work in the area 
(Swansea and Antwerp)66 (search repeated 6.3.18). 
Cochrane reviews67 68 on optimising prescribing in care 
homes identified medication reviews, case-conferencing, 
education initiatives, decision-support technology and 
information transfer trials, but no structured medicines’ 
monitoring. Other side-effect checklists include only anti-
psychotics or posture and movement problems, despite 
the prevalence of mental health polypharmacy,72 73 are 
designed for patient self-administration (our participants 
are not well enough) or the measurement of subjective 
beliefs, are very brief and lack guidelines for action.66 69 70 
Uniquely, ADRe includes estimates of change to prompt 
referral or actions and starts with vital signs, including 
postural hypotension and oxygen saturation: these have 
been pivotal in obtaining prescriber reviews.19 We recog-
nise that physical health medicines, particularly cardio-
vascular medicines and analgesics, are important causes 
of ADRs,16 and ADRe’s guidelines indicate this and seek 
to support clinical judgement in addressing the causes 
of problems identified. Work on decision support74 and 
multidisciplinary team communication75 is underway, but 
ADRe remains unique.
data collection
We are undertaking interviews and non-participant obser-
vations with the participants of our five previous homes19 
and five newly recruited care homes. We are observing 
nurses administering the ADRe Profiles, noting any 
discrepancies between ‘as intended’ and ‘as operation-
alised’, for example, items omitted or re-ordered and diffi-
culties with equipment. Consistency between fieldworkers 
is ensured by preparation at team meetings and struc-
tured interview and observation schedules derived from 
earlier work. We aim for contextual and detailed descrip-
tions of participants’ experiences of the ADRe profile 
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and nurse-led medicines’ monitoring as an innovative 
and incompletely understood social situation.76 77 We 
shall explore interest in combining ADRe with digital 
technologies and non-invasive patient monitoring78 and 
expanding to other medication groups (figure 2).
Observations
In each home, we shall observe three episodes of care 
involving ADRe administration and record events using 
templates and freehand notes, as previously described.22 
We shall note how medicines’ monitoring is 
operationalised, practical barriers and facilitators and any 
clinical gains and harms.21 Observations will be followed 
by debriefing to discuss any findings from the profile in 
relation to the guidelines and any suggestions for modi-
fying practice.
Completed profiles plus the MAR charts will be passed 
to the study pharmacist for review. The pharmacist will 
make written recommendations as to how problems 
identified on ADRe might be addressed by changes in 
prescribing and raise awareness of any modifications of 
Figure 3 Logic model for ADRe: resources–actions–outputs–outcomes–goals. ADR, adverse drug reaction. GI, gastro-
intestinal; OT, occupational therapist; UTI, urinary tract infenction. 
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nursing care or additional monitoring needed. These 
are one-off reviews by a consultant pharmacist with care 
home expertise for the purpose of this study. Care home 
managers will be asked to facilitate any changes needed. 
For urgent matters, prescribers will be contacted directly.
Interviews
Interviewing end users as key stakeholders48 will explore 
experiences of ADRs, drivers of change, barriers and 
facilitators of medicines’ monitoring to identify differing 
concerns and facilitate mutual understanding and joint 
working.79 This will determine the best way to integrate 
and embed medicines’ monitoring in routine care, relate 
the profile to processes and outcomes of care and develop 
implementation strategies.
data analysis
Observational data will be used to compile a record 
of clinical benefits and disbenefits and pharmacist 
recommendations.
Analysis of interviews will be based on the constant 
comparative method80 to identify predictors of successful 
adoption and any changes to profiles, working arrange-
ments and oversight needed to embed use. This system-
atic, reiterative method of comparing and contrasting 
emerging codes, categories and concepts ensures that 
theoretical perspectives are embedded in the data. Inter-
views and observation fieldwork will be coded, catego-
rised, analysed and closely interpreted by at least two 
researchers and discussed at team meetings, with consis-
tency checks.81 The first 10 and 20 interview transcriptions 
will be reviewed for coding, categorisation, saturation, 
cases in contrast and the development of the sample.
Data from interviews, observations and pharmacist 
feedback will be integrated to enhance understanding, 
depth, rigour and validity.82 Previous themes of clinical 
gains, barriers, facilitators and proposals for change offer 
a provisional template.21 22 51 Final codes and themes and 
data saturation will reflect collective decisions.
outcomes
Outcome measures are clinical impact and barriers to 
and facilitators of sustainability.
Impact
The primary outcome of the observations is evidence of 
clinical impact (anticipated and actual), which will be 
described as: number of participants benefiting from 
ADRe, additional care or nursing actions and number 
and nature of problems addressed (including prescrip-
tion changes), as noted on ADRe or reported by nurses. 
The outcome of pharmacist’s reviews will be the number 
and nature of recommendations to (1) prescribers and 
(2) nurses made using ADRe.
Sustainability
Barriers (eg, time, interruptions, distractions) and facili-
tators of ADRe administration and adoption, the changes 
needed to embed ADRe into routine care (figure 3, online 
supplementary file 2) and factors that would promote or 
block adoption of ADRe and new technologies will be 
identified in thematic analyses of interviews, supported 
by observation data.
Ethics
Approval was obtained on 17 February 2017 from 
Wales Research Ethics Committee 6 who will review any 
protocol modifications (reference no 16/WA/0358, IRAS 
ID 213050). The study is sponsored by Swansea Univer-
sity. Written and verbal information is offered, and poten-
tial participants are given as much time as they need to 
decide whether to participate. Written informed consent 
is sought for all interviews, observations, debriefing and 
review of documentation or accounts. As an addition to 
routine nursing documentation, embedding ADRe into 
routine documentation falls outside the NHS Health 
Research Authority definition of research,83 and cluster 
studies do not follow the same principles as individually 
randomised trials in requiring individual participants’ 
consent for non-intrusive research.84–87 Non-intrusive 
clinical research, including retrospective review of patient 
notes, where there is neither inconvenience nor hazard 
to patients, does not usually require expressed consent.88 
The only questions ADRe asks are those that should be 
asked as part of routine care89–92 and confer no greater 
risk of harm.88 All questions relate to potential ADRs and 
physical health problems and are designed to ensure 
patient safety.
The study is not unduly invasive, in that it does not go 
beyond the experiences of daily life or routine medical 
examination,93 and all previous participants bene-
fited.19 22–24 In all 10 care homes, three residents meeting 
the inclusion criteria are approached by their nurses and 
asked to consent to researchers observing administration 
of ADRe and reviewing their clinical records, including 
completed profiles and medicines charts. Signed consent 
is taken by registered nurses fully aware of the Mental 
Capacity Act 2005.94 For those without capacity to consent, 
consultees are approached. For many participants, the 
consultee is a relative in regular contact; however, for 
residents who have no regular visitors and rely on profes-
sional support, the consultee may be a care home clini-
cian who knows the resident and is not involved in the 
research.93 In the unlikely event that we observe breaches 
of the NMC code of conduct,95 these will be pursued in 
accordance with the code.
data handing
All data are anonymised on collection and kept strictly 
confidential. Participants and care homes are assigned 
study numbers, and personal names only appear on 
consent forms. Service users’ ages, sex, medicines and 
medical conditions are recorded. Professionals’ roles, 
but not personal information, are recorded. Data are 
managed in accordance with the Data Protection Act 
199896 and the Research Governance Framework for 
Health & Care Wales (2010).97
 o
n
 2 O
ctober 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-023377 on 28 September 2018. Downloaded from 
8 Jordan S, et al. BMJ Open 2018;8:e023377. doi:10.1136/bmjopen-2018-023377
Open access 
status of the study
Care homes have been recruited, and data collection has 
started.
dIsCussIon
Prescribed medicines (any) benefit between 4% and 
25% of patients,98 whereas ADRs affect 7.8% (95% CI 
7.2% to 8.4%) of patients in primary care,11 11.0% (95% 
CI 5.1% to 16.8%) of hospitalised patients,99 killing 
0.25%,100 and 4.8%–37% of people with cognitive impair-
ment.16 However, systematic review indicates that health-
care professionals consistently underestimate harms 
and overestimate benefits of prescribed medicines.101 
Consultations are often brief, informal and led by profes-
sionals with, at most, a general inquiry as to ‘any side 
effects’.102 103 By avoiding detailed directed questions, 
professionals risk failing to capture patients’ experiences 
of ADRs104 and allow ADRs to worsen, unmonitored, to 
the point of requiring secondary care, for example, due 
to falls105 106 or pneumonia.107 108 Structured monitoring 
facilitates social coproduction and recognition of prob-
lems that may be ADRs, as listed in the BNF and SmPCs, 
circumventing non-disclosure or denial by patients and 
professionals.66 109 110 Insidious onset of problems, famil-
iarity with the patient and overlap between some ADRs 
(such as falling, incontinence, sedation, confusion) and 
the signs and symptoms of ageing or disease militate 
against ADR recognition by fostering entrapment by prior 
expectation.111 Failure to recognise ADRs is attributable, 
in part, to their complexity and diversity, difficulties in 
remembering full lists of possible ADRs (10–20 per medi-
cine) for multiple medicines (up to 20 per patient) and 
any associated deficits in education,112 knowledge113–116 
or patients’ and nurses’ confidence in their knowledge.55 
ADRs to prescribed medicines are not coincident with 
prescribing (they develop after the doctor has left); 
therefore, a mechanism is needed to transfer informa-
tion117 from patient to prescriber, across geographical 
and social distance. Comprehensive, formalised struc-
tured monitoring by administration of the ADRe Profile 
before scheduled appointments or reviews has potential 
to bridge this hiatus in communications and care, intro-
duce a nursing voice into the refinement of therapeutic 
regimens and involve nurses in ADR management.118
systematised, protective reporting: before not after a serious 
Adr
The published literature on ADRs is limited by non-dis-
closure of data,119 whereas ADR recognition has become 
reliant on expert decisions, detached from social 
contexts.110 Most evidence of harm comes from retro-
spective analyses of large databases, and each analytical 
method has its proponents and detractors.120 Some 5% 
of serious ADRs are reported via spontaneous reporting 
systems, such as the iconic ‘yellow card’ scheme.121 
Reliance on volunteer reporting renders spontaneous 
reporting systems vulnerable to respondent and notoriety 
biases.122 123
Pharmacovigilance focuses on regulators’ assess-
ments of any need to discontinue or restrict medicines 
and usually focuses on serious, rare and unpredictable 
ADRs, such as torsade, anaphylaxis or acute liver failure, 
rather than mundane but socially disabling ADRs, such 
as tremors, xerostomia, incontinence and sedation.124 125 
Similarly, prescribing indicators track potentially prob-
lematic medicines, rather than patient outcomes.126 ADRe 
has a different focus: it is a protective strategy, aiming to 
prevent ADRs by regular comprehensive monitoring, 
embedding problem recognition in local contexts, as 
illustrated from earlier work (online supplementary file 
2).
Potential cost savings
Decision aids in several contexts enhance professionals’ 
perceptions of knowledge and judgement, but at the 
cost of extended consultation time.127 Our intervention 
involves nurses or care assistants, who know their patients, 
with support from registered nurses. We estimated ~£20 
for an initial profile completion.19 Monthly administra-
tion would therefore be offset by the estimated additional 
medication costs incurred by patients with ADRs (US$31.7 
or £23 per month, exchange rate: 1USD$=0.79 GBP as of 
22 March 2018).128
ADEs (underprescribing or overprescribing of medi-
cines) (glossary, online supplementary file 1) are respon-
sible for 8% of healthcare spend in the USA.129 In Sweden, 
9.5% of direct healthcare costs are attributed to ADEs: 
each ADE incurs direct treatment costs of US$444.9, 
264–625 (£320, 10–449) for the initial episode.130 
However, the average societal cost of an ADE illness is 
higher—US$6235.0 (5442.8 to 7027.2) (£4481, 3911–
5050), comprising direct costs for the illness of US$2830.1 
(2260.7 to 3399.4) (£2034, 1625–2443) (45%) plus indi-
rect costs for lost earnings or other commitments of 
US$3404.9 (2899.3 to 3910.4) (£2447 (£2083–2809.8)).130 
In the Netherlands, each preventable medication-related 
admission costs €5461 (£4866),131 and each admission 
due to a fall costs ~£20 k,132 suggesting that improved 
falls risk assessments, vision checks, reduction of sedatives 
and antipsychotics following use of ADRe could generate 
significant savings. Additional costs relating to pain, 
sedation, poor oral hygiene and poor eyesight, and their 
amelioration, are hard to quantify, but affect the quality 
of life,19 which is generally lower in those with ADRs or 
undertreated conditions.128 Ten completions of ADRe 
cost ~£200 in nursing time, and some 10% of participants 
have a serious ADR, that would have led to admission 
costing ~£4 k,9 131 prevented by ADRe.19 22 24
Policy fit
Information alone rarely changes clinical practice.133 More 
surprisingly, consultant-led medication review,134 decision 
support,135 academic detailing,136 deprescribing137 and 
pharmacist-led interventions did not enhance clinical 
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outcomes30 or quality of life, and Cochrane reviewers 
found evidence for implementation to be equivocal and 
low quality.67 68 Some psychosocial person-centred care 
initiatives reduce the prescribing of antipsychotics, but 
are time intensive, often with ill-defined clinical outcomes 
and unsupported by research evidence.31 However, time, 
not weak evidence, is the major barrier to therapeutic 
drug monitoring138 and shared decision-making.61
Faced with resource constraints, increasing demand 
from an ageing population, concerns that social class gradi-
ents in antipsychotic prescribing139 may be compounding 
health inequalities, and stretched services, Welsh govern-
ment’s attention has focused on avoidable harm, primum 
non nocere, and minimising any adverse effects of care.66 117 
Any harm from medicines is obfuscated by professional 
boundaries: prescribers (GPs and specialists) typically see 
residents for 7–15 min at review, whereas those working 
in care homes see the subtle, insidious adverse effects of 
medicines every day, but may not recognise their prov-
enance without ADRe support. Deprescribing is often 
a complex decision based on detailed conversations, 
making repeat prescribing a quicker and easier option140: 
ADRe facilitates deprescribing by gathering the informa-
tion needed.
Some medicines' management strategies focus on record 
keeping and storage, rather than patient monitoring.60 
However, other policy documents note that those adminis-
tering medicines are responsible for regularly monitoring 
patients and reporting to prescribers any changes that may 
emanate from medication or if assessment of the patient 
indicates that the medicine is no longer suitable.38 141 Mental 
health medicines have many adverse effects, cautions and 
contraindications—and few can remember them all. There-
fore, ADRe obviates reliance on memory by packaging this 
knowledge into a format that is convenient for passing to 
prescribers and amenable for incorporation into electronic 
records. However, to work in care homes, interventions 
improving quality of life must be congruent with staff atti-
tudes, priorities, time allocation,142 experience, values143 
and shared understandings.144
study limitations
Generalisation
Our study involves non-random selection of a sample 
of care homes in one University Health Board area in 
South West Wales, and further studies will be needed 
to confirm the transferability of findings to other local 
areas. We acknowledge the potential for volunteer bias 
in all research designs145 and the difficulties (ethical 
and practical) of obtaining information on the reasons 
for non-response to research invitations. Similarly, the 
pharmacist reviews are compiled by one expert pharma-
cist, to test the feasibility of this approach, and we do not 
know if less experienced pharmacists would react differ-
ently. Only policy initiatives can determine whether our 
findings will transfer to struggling organisations,37 as 
they are less likely to volunteer for research projects, 
and may be less likely to have sufficient staff to offer 
support to those withdrawing from antipsychotics.146 
Participant recruitment to observations and interviews 
is at the discretion of nurses, and we cannot discount 
the possibility of selection bias. Generalisation of find-
ings will depend on logical inferences.147 However, 
medicines management is a widespread problem, in 
urgent need of effective interventions.1
Study size
We recognise that 30 interviews encompassing the full 
range of stakeholders may not offer data saturation in 
some categories, particularly the ‘hard to reach’ category 
of national strategic leads. We estimated sample size53 54 to 
plan ahead before applying for funding and acknowledge 
the limitations of this pragmatic approach, which will not 
affect data analysis. Our analysis will be based on common 
themes from multiple perspectives. When assessing prac-
tical adequacy, readers will be asked to juxtapose the 
clinical impact of ADRe observed here with findings of 
previous studies.19 22–24 52 56 Resource constraints restrict 
each resident to a single observation, and it may not be 
possible to follow progress to ascertain whether recom-
mendations have been enacted.
Nurses’ reporting
ADRe relies on nurses’ reports of ADRs, and many resi-
dents are non-verbal. It is, therefore, vulnerable to 
nurses’ interpretation, and we acknowledge that nurses 
may under-report residents’ ADRs.148 However, we are 
exploring how ADRe enhances delivery of care and 
communications and cannot discount the possibility that 
some problems may be misreported. Time pressures in 
the NHS usually limit doctor–patient contact to 7–15 min, 
insufficient to review all aspects of care, although some 
50% of the items on ADRe can be identified in care 
homes’ notes, the information takes ~1 hour to retrieve.19 
We therefore suggest that ADRe, despite limitations, 
might improve care.
Prescription-based inclusion criteria
Everyone prescribed mental health medicines is vulner-
able to their adverse effects: pharmacodynamics does 
not respect diagnostic categories and service boundaries. 
Dementia diagnoses are often not recorded in the UK.149 
Accordingly, our inclusion criteria centre on prescrip-
tions and associated vulnerability to ADRs and are not 
restricted by diagnostic groups. Residents’ medical 
records containing diagnoses are held by GPs and are not 
available in care homes.
ConClusIon
The WHO’s Third Patient Safety Challenge ‘Medi-
cation Without Harm’ calls for action to strengthen 
monitoring systems and facilitate improvements in 
monitoring practices.1 150 The previous WHO Global 
Patient Safety Challenge was effectively met by a check-
list approach.151 We hope to build a consensus around a 
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similar communication approach to enhance the systems 
and practices of medication management. ADRe could 
contribute to the WHO ‘Medication Without Harm’ 
challenge, complementing and reinforcing error-re-
duction strategies71 and addressing problems identified 
by WHO,150 NICE,8 DoH,13 Public Health Wales,14 the 
Older People’s Commissioner,25 the Andrews’ Report28 
and others.1 152 However, political will, consensus, 
organisational commitment,14 morale,143 activation of a 
shared sense of urgency and flexible levels of engage-
ment43 will determine whether ADRe can be sustained 
and ADRs addressed.
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